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Abstract: Current strategies for the mass administration of antimalarial drugs demand oral
formulations to target the asexual Plasmodium stages in the peripheral bloodstream, whereas
recommendations for future interventions stress the importance of also targeting the transmission
stages of the parasite as it passes between humans and mosquitoes. Orally administered
polyamidoamine (PAA) nanoparticles conjugated to chloroquine reached the blood circulation and
cured Plasmodium yoelii-infected mice, slightly improving the activity of the free drug and inducing
in the animals immunity against malaria. Liquid chromatography with tandem mass spectrometry
analysis of affinity chromatography-purified PAA ligands suggested a high adhesiveness of PAAs
to Plasmodium falciparum proteins, which might be the mechanism responsible for the preferential
binding of PAAs to Plasmodium-infected erythrocytes vs. non-infected red blood cells. The weak
antimalarial activity of some PAAs was found to operate through inhibition of parasite invasion,
whereas the observed polymer intake by macrophages indicated a potential of PAAs for the treatment
of certain coinfections such as Plasmodium and Leishmania. When fluorescein-labeled PAAs were fed
to females of the malaria mosquito vectors Anopheles atroparvus and Anopheles gambiae, persistent
fluorescence was observed in the midgut and in other insect’s tissues. These results present PAAs as
a versatile platform for the encapsulation of orally administered antimalarial drugs and for direct
administration of antimalarials to mosquitoes, targeting mosquito stages of Plasmodium.
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1. Introduction
Oral administration of antimalarial drugs is the best route in terms of patient compliance:
it makes people feel less sick and reduces medical cost because of its ease of administration [1].
Currently used antimalarials, however, are not easily dissolved in aqueous solvents or show poor
membrane permeability, which, in addition to their sensitivity to degradation, makes their oral
delivery challenging [2]. To overcome this obstacle, incorporating polymers in the formulation is a
strategy that has been used to give drugs increased solubility and membrane-trespassing capacity,
and to protect labile compounds from digestive enzymes and extreme pH variations [3]. Polymeric
nanocarriers are generally stable during gastrointestinal tract (GIT) transit [4], and given the versatility
associated with their constituent materials (natural, semisynthetic or synthetic) as well as the variety of
methods by which they are processed (e.g., spray-drying, emulsion techniques, precipitation, solvent
extraction/evaporation), they can be used for the delivery of a wide range of cargoes [3]. Furthermore,
advances in polymer chemistry enable exquisite control over the nanoarchitecture and biophysical
properties of polymeric nanocarriers, which facilitates controlled or triggered drug delivery [5].
Polycations, in particular, are especially adept at oral administration because of their capacity to
promote drug absorption by a variety of mechanisms, among which an increased GIT retention due
to their mucoadhesive properties [6]. The systemic exposure to orally delivered polycations is low
compared to the parenteral route, and therefore better tolerance is expected. Certain polycations
such as polyamidoamine (PAA) polymers have the capacity to increase the epithelial permeability to
conjugated drugs and biomacromolecules [6], mainly by potentiating paracellular transport although
some systems may boost transcytotic passage as well. Also, anionic PAA polymers have been described
as more efficiently transported across the intestinal epithelium, primarily through the paracellular
route [7]. However, despite numerous studies on oral PAA bioavailability [6–10], it remains unexplored
to what extent this administration method provides the necessary plasma drug concentrations for the
pharmaceutical development of oral antimalarial formulations targeting Plasmodium parasites inside
red blood cells (RBCs).
The PAA structures AGMA1 and ISA23, with respective isoelectric points of 10.0 and 5.5, had been
explored for the encapsulation and targeted delivery of the antimalarial drugs chloroquine (CQ) and
primaquine [11]. Fluorescence-assisted cell sorting, confocal fluorescence microscopy, and transmission
electron microscopy results indicated that AGMA1 and ISA23 polymers with hydrodynamic radii
around 7 nm had specific targeting to Plasmodium-infected RBCs (pRBCs) vs. non-infected erythrocytes,
and to intraerythrocytic Plasmodium falciparum and Plasmodium yoelii merozoites, whereas AGMA1 itself
exhibited a mild antimalarial activity. Mice inoculated with a lethal strain of the murine malaria species
P. yoelii were freed of parasites after intraperitoneal administration of PAA-encapsulated CQ, whereas
the same amount of free drug was unable to cure the animals.
Notwithstanding these promising results, several questions remained open, among them which
is the mechanism behind the specificity of binding of PAAs to pRBCs, and whether PAAs could
be applied to the current need of mass drug administration for non-complicated malaria by oral
delivery [1]. With these two main objectives, previous synthetic protocols [11] have been adapted
to obtain larger PAA structures that will take longer to degrade in the aggressive GIT environment.
We present the characterization of these new polymers in terms of structure, cellular and subcellular
targeting, and antimalarial activity after CQ encapsulation, both in in vitro growth inhibition assays of
the human malaria parasite P. falciparum and in in vivo experiments where P. yoelii-infected mice have
been orally administered CQ-loaded PAAs. We also communicate the preliminary results of a radically
new approach to malaria control and elimination, where PAAs were orally fed to the malaria mosquito
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vectors Anopheles atroparvus and Anopheles gambiae in preparation for future strategies that will target
Plasmodium stages in the insect [12].
2. Materials and Methods
2.1. Polyamidoamine (PAA) Synthesis and Characterization
Unless otherwise indicated, all reagents were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Linear ISA23 [13], ISA1 [14], AGMA1 [15] and ARGO7 [16] were synthesized by stepwise
Michael-type addition of prim- or sec-amines to bisacrylamides, as previously described [11], extending
the reaction time to 14 days. Previously reported methods were followed for fluorescein isothiocyanate
(FITC) labeling of the polymers [11,15] and for their loading with CQ [11]. FITC-labeled PAAs were
obtained by reaction of FITC with PAAs bearing limited amounts of NH2 pendants, which were
synthesized as previously reported for AGMA1 [15]. Therefore, fluorescein is bound to PAAs through
a urethan function, which has proved to be extremely stable in physiological conditions [17]. The
conjugation of PAAs with FITC was finally confirmed by NMR. To assess the encapsulated CQ content
just before in vitro and in vivo analyses, PAAs were hydrolyzed overnight with 0.1 M NaOH, pH was
neutralized with 5 M HCl to solubilize the precipitated drug, and CQ was determined by measuring
A340 nm; a calibration curve was prepared with known concentrations of CQ diphosphate identically
processed. The incorporation of sulfhydryl groups in PAAs was done using standard amino-functional
pyridyl disulfide chemistry [18,19], which is described in detail in the Supplementary Materials for the
three PAAs later used for in vivo assays. The nanoparticle size was assessed by nanoparticle tracking
analysis, using a NanoSight LM10 (Malvern Instruments Ltd., Malvern, UK). The experiments were
performed in phosphate-buffered saline (PBS) at 25 ◦C at a concentration of 10 mg/mL, except for
ARGO7 which was dissolved at 2.5 mg/mL. For scanning electron microscopy (SEM) analysis, PAAs
were dissolved in isopropanol at 5 µg/mL. Fifteen microliters of this PAA solution were placed on a Si
sheet (MicroChemicals, Ulm, Germany) previously cleaned, first with acetone, then with ethanol, and
finally with isopropanol. Samples were allowed to dry for 48 h at room temperature (RT, ca. 20 ◦C)
and imaged with a Nova NanoSEM™ 230 scanning electron microscope (FEI Company, Eindhoven,
The Netherlands). For atomic force microscopy (AFM) analysis, 10 µL of 1 mg/mL polymer solutions
in double-deionized water (ddH2O; MilliQ system, Millipore, Burlington, MA, USA) were deposited
on cleaved mica substrates and, after an adsorption time of about 5 min, 40–60 µL of ddH2O were
added. High-resolution images were obtained with a MultiMode 8 atomic force microscope equipped
with a NanoScope V controller (Bruker Corporation, Billerica, MA, USA) operating in ScanAsyst mode
in liquid. ScanAsyst-Fluid+ probes (Bruker Corporation) were used in the experiments.
2.2. Matrix-Assisted Laser Desorption/Ionization Tandem Time-of-Flight (MALDI TOF/TOF) Analysis
PAA samples (1 mg/mL) were incubated for the times indicated in simulated fasted-state gastric
fluid (80 µM Na-taurocholate, 34.2 mM NaCl, adjusted with HCl to pH 1.6). MALDI mass spectra
were recorded using a 4800 Plus MALDI TOF/TOF (ABSciex, Framingham, MA, USA) instrument
equipped with Nd:YAG solid state laser (355 nm, 200 Hz frequency, 3–7 ns pulse). Analyses were
performed in both positive linear and reflector mode. Solutions of the samples (1 µL) were mixed with
1 µL of a saturated matrix solution of 2,5-dihydroxybenzoic acid in acetonitrile; 1 µL of this mixture
was spotted on the sample plate and left to dry before the analysis.
2.3. Plasmodium falciparum Cell Culture and Parasite Growth Inhibition, Hemolysis and Unspecific
Cytotoxicity Assays
P. falciparum 3D7 in vitro cultures were prepared as described elsewhere [20,21]. Parasites were
grown at 37 ◦C in T25 flasks (SPL Life Sciences, Gyeonggi-do, Korea) containing human RBCs of
blood group type B in a Roswell Park Memorial Institute (RPMI) medium supplemented with 5 g/L
Albumax II and 2 mM glutamine (complete RPMI), following previously established conditions [22].
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Two hundred microliters of these Plasmodium cultures were plated in 96-well plates and incubated for
48 h at 37 ◦C in the presence of free drugs and PAA-drug conjugates dissolved in RPMI. Parasitemia was
determined by microscopic counting of blood smears or by flow cytometry as previously described [20].
The human blood used in this work was from voluntary donors and commercially obtained
from the Banc de Sang i Teixits (www.bancsang.net). Blood was not collected specifically for this
research; the purchased units had been discarded for transfusion, usually because of an excess of
blood relative to anticoagulant solution. Prior to their use, blood units underwent the analytical checks
specified in the current legislation. Before being delivered to us, unit data were anonymized and
irreversibly dissociated, and any identification tag or label had been removed in order to guarantee the
non-identification of the blood donor. No blood data were or will be supplied, in accordance with the
current Ley Orgánica de Protección de Datos and Ley de Investigación Biomédica. The blood samples will
not be used for studies other than those made explicit in this research.
Merozoite invasion inhibition assays were performed as previously described [23], in 150 µL of
culture treated with PAAs dissolved in RPMI. The following equations were used to assess invasion
and maturation rates:
Invasion =
rings day n
(trophozoites + schizonts) day n− 1 (1)
Maturation =
(trophozoites + schizonts) day n
rings day n− 1 (2)
Hemolysis and unspecific cytotoxicity assays were done as described elsewhere [20]. For AGMA1,
cytotoxicity assays were done in Phenol Red-free medium.
2.4. Cell Targeting Analysis
Living P. falciparum 3D7 cultures were stained for 30 min with 4 µg/mL of the DNA dye Hoechst
33342 (λex/em: 350/461 nm). After three washes with complete or incomplete RPMI the cells were
incubated with gentle stirring in the presence of 0.25 mg/mL PAA-FITC for 90 min in complete or
incomplete RPMI at 37 ◦C. After washing with PBS, nonfixed samples were placed in an eight-well
chamber slide system (Lab-Tek®II, catalog number 155409). Confocal fluorescence microscopy analysis
was done with a TCS SP5 laser scanning confocal microscope (Leica, Vienna, Austria) equipped with a
DMI6000 inverted microscope, blue diode (405 nm), Argon (458/476/488/496/514 nm), diode pumped
solid state (561 nm) and HeNe (594/633 nm) lasers and PLAN APO 63× oil (NA 1.4) immersion
objective lens. For flow cytometry analysis, pRBCs were diluted in PBS to a final concentration of
1−10 × 106 cells/mL, and samples were analyzed using a LSRFortessa™ flow cytometer instrument
(BD Biosciences, San Jose, CA, USA) set up with the five-laser, 20-parameter standard configuration,
as previously described [11].
A macrophage cell line of mouse tumor origin (RAW 264.7) was grown in RPMI medium
supplemented with 10% fetal calf serum, 100 µg/mL streptomycin, and 100 U/mL penicillin (complete
medium) at 37 ◦C in an atmosphere containing 5% CO2. Macrophages (300 µL, 5 × 104 cells/mL) were
cultured in an eight-well Lab-Tek chamber slide system. After 24 h those cells that did not adhere
were washed out; 48 h later, the culture was washed three times with PBS, and macrophages were
treated in RPMI with 300 µL of PAA-FITC at 0.5 mg/mL. Samples were incubated for 90 min in the
same conditions before washing PAAs with RPMI and staining plasma membranes with 5 µg/mL
WGA-rhodamine (10 min, RT). Wells were then washed with RPMI and refilled with 300 µL complete
medium before proceeding to observation of the fluorescence of FITC and rhodamine (respective
λex/λem: 488/520 and 553/627 nm) with an IX51 inverted fluorescence microscope (Olympus, Tokyo,
Japan). Confocal fluorescence microscopy images of [PAA-FITC]-treated macrophages were obtained
as described above for RBCs, including Hoechst 33342 staining of nuclei.
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2.5. Generation of Polyclonal Antibodies against PAAs
Immunization of rabbits was done in the facilities of the Animal Experimentation Services from
the Faculty of Pharmacy at the University of Barcelona (UB) following standard protocols. The animal
study was approved by the UB Animal Research Committee and the Government of Catalonia, and
conducted in accordance with the Guide for the Care and Use of Laboratory Animals published by
the U.S. National Institutes of Health [24]. PAAs were coupled to the carrier protein ovoalbumin and
injected to two NZW rabbit females (Minimal Disease Level quality), following this immunization
calendar: day 0, preimmune blood collection (reference for antibody production induced by the
antigen injection) and primary immunization (intradermal injections at six to eight sites per rabbit of
an aggregated amount of 250 µg PAA in a total volume of 1 mL Freund’s complete adjuvant); boosters
were administered every 21 days, with the same amount of antigen emulsified in Freund’s incomplete
adjuvant. Antibody titer was determined by enzyme-linked immunosorbent assay (ELISA, see below)
of partial bleedings between immunizations, at days 52, 73, and 93, when the animals were euthanized
and exsanguinated.
Serum antibodies to PAAs were assayed using an internal standard operating procedure. Briefly,
flat-bottom 96-well ELISA plates (Nunc®) were coated at 4 ◦C overnight with 100 ng/well of antigen
conjugated to bovine serum albumin (BSA) diluted in 15 mM Na2CO3, 35 mM NaHCO3, pH 9.6. Plates
were washed with 0.1% Tween 20 in PBS (PBS-T) and then blocked with 5% skimmed milk in PBS (2 h,
RT). After the plates were washed again, the test serum was diluted in 0.1% BSA, 0.05% Tween 20 in PBS,
added to antigen-coated wells in triplicate, and incubated for 2 h at RT. A duplicate control dilution
series of a non-hyperimmune rabbit antiserum, obtained at day zero, was also included in each plate.
After extensive washing, the plates were incubated for 2 h with peroxidase-labeled goat anti-rabbit IgG
(Bio-Rad, Hercules, CA, USA) diluted in the same buffer. Bound antibodies were measured by adding
the substrate solution (SIGMAFAST™ OPD, o-phenylenediamine dihydrochloride) and determining
A450 nm with a Multilabel Victor3 plate reader (Perkin Elmer, Turku, Finland). A 4 Parameter Logistic
(4PL) nonlinear regression model was used in all ELISA assays for the antibody titer calculation. Sera
were finally stored at −20 ◦C until use.
Polyclonal antibodies against PAAs present in the rabbit serum (15 mg total Ig/mL) were tested
in a dot blot assay. Briefly, 3 µL of 3 mg PAA/mL dilutions in ddH2O were applied and allowed to dry
on a nitrocellulose membrane (0.45 µm, Bio-Rad, catalog number 1620145). As a positive control, 3 µL
of a 1:25,000 serum dilution were spotted on the same membrane. Non-specific sites were blocked
with 5% BSA in TBS-T (0.05% Tween 20, 150 mM NaCl, 20 mM Tris-HCl, pH 7.5) for 1 h at RT. Then the
membrane was first incubated (30 min, RT) with rabbit plasma containing the polyclonal antibodies
dissolved in TBS-T at 0.15 mg total Ig/mL (1:100 dilution), washed (TBS-T, 3× 5 min), and then treated
with a secondary goat anti-rabbit antibody conjugated to horseradish peroxidase (AB6721, Abcam,
Cambridge, UK) in TBS-T at 1 µg/mL (30 min, RT), followed by three 5-min washes with TBS-T and
one wash with TBS (TBS-T without Tween 20). Finally, the membrane was incubated with ECL Prime
Western Blotting Detection Reagent (Luminol, Amersham, UK) for 30–60 s and scanned (ImageQuant
LAS4000, GE Healthcare, Chicago, IL, USA).
2.6. Affinity Chromatography
Half a milliliter of SulfoLink Coupling Resin, activated with iodoacetyl groups (Thermo Fisher
Scientific, Waltham, MA, USA), was added to a snap cap spin column (Thermo Scientific Pierce,
Waltham, MA, USA) to achieve a final column volume of 0.25 mL. For the covalent immobilization of
PAAs functionalized with sulfhydryl groups (PAA-SH) on the sulfhydryl-reacting columns, these were
equilibrated with coupling buffer (CB: 5 mM EDTA, 50 mM Tris-HCl, pH 8.5) and loaded with 0.5 mL of
20 mg/mL PAA-SH in CB. After gentle mixing (RT, 15 min) the columns were placed upright, and after
30 min at RT they were centrifuged (1 min, 1000 g) and washed with CB. Coupling efficacy was assessed
by determining the amount of free sulfhydryl groups in the samples before and after passing through
the column. Briefly, a calibration curve was prepared with dithiothreitol dissolved in 130 µL of reaction
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buffer (RB: 0.1 M sodium phosphate, 1 mM EDTA, pH 8.0), to which 2.5 µL of a 4 mg/mL Ellman’s
reagent solution in RB were added. After 15 min incubation at RT, A412 nm was determined. Then
5 mg/mL solutions of each PAA-SH in RB were processed in the same way. Unoccupied binding sites
were blocked by adding 2 column volumes of quenching buffer (50 mM L-Cys-HCl in CB), followed by
gentle mixing, upright incubation, centrifugation, and washing as above. Two milligrams of protein in
0.5 mL of fresh saponin extracts [25] of RBCs or pRBCs synchronized with 70% Percoll (GE Healthcare)
at Plasmodium late stages were loaded onto each column. After mixing, upright incubation (1 h) and
centrifugation as above, columns were washed with 3 to 10 column volumes of PBS. Bound proteins
were eluted with a pre-warmed (55 ◦C) elution buffer (1× Laemmli sample buffer, supplemented
with 355 mM 2-mercaptoethanol). For SDS-polyacrylamide gel electrophoresis (PAGE) analysis,
samples were heated at 90 ◦C for 5 min in an elution buffer, and electrophoresed in 1 mm-thick 12.5%
SDS-polyacrylamide gels (Mini Protean II System, Bio-Rad), which were silver-stained as previously
described [26]. For the identification of PAA-binding pRBC proteins (see below), a second gel was fixed
with acetic acid:ethanol:ddH2O (1:4:5) and stained with colloidal Coomassie Blue in 20% methanol.
2.7. Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Colloidal Coomassie Blue-stained gel bands were digested separately and tryptic digests were
pooled to be analyzed by LC-MS/MS in a single injection. For manual in-gel digestion of proteins with
trypsin, excised SDS-PAGE bands were washed sequentially with 25 mM NH4HCO3 and acetonitrile
(ACN), reduced in 20 mM DTT (60 min, 56 ◦C), alkylated in 50 mM iodoacetamide (30 min, 30 ◦C,
protected from light), and digested with 1.2 µg of porcine trypsin (sequencing grade modified Trypsin
Gold, Promega, Madison, WI, USA) for 16 h at 37 ◦C. The resulting peptides were extracted from the
gel matrix with 10% formic acid (FA) and ACN, and the extracts from each lane were pooled and dried
in a SpeedVac concentrator.
Mass spectrometry was performed in a NanoAcquity HPLC system (Waters, Milford, MA, USA)
coupled to an OrbitrapVelos mass spectrometer (Thermo Scientific). Dried extracts were taken up in 1%
FA and an aliquot was injected into the liquid chromatography system equipped with a reverse-phase
C18 column (75 µm internal diameter, 25 cm length, 1.7 µm particle NanoAcquity BEH column, Waters),
with a mobile phase 1–40% B gradient in 60 min followed by a 40–60% B gradient in 10 min (A: 0.1%
FA in water; B: 0.1% FA in ACN) and a flow rate of 250 nL/min. Eluted peptides were ionized in an
emitter needle (PicoTipTM, New Objective, Zurich, Switzerland) with an applied spray voltage of
2 KV. A 300–1700 m/z range of peptide masses was analyzed in data dependent mode where a full
scan was acquired with a resolution of 60,000 full width at half maximum at 400 m/z. Within this
range, the 15 most abundant peptides (≥500 counts) were selected from each scan and fragmented
in the linear ion trap using collision-induced dissociation (38% normalized collision energy) with He
as the collision gas. The scan time settings were: Full MS: 250 ms (1 microscan) and MSn: 120 ms.
Generated raw data files were collected with Thermo Xcalibur (v. 2.2).
A database was created by merging all human protein entries present in the Swiss Prot database
with all entries for Plasmodium present in the Uniprot database (January 2016). A small database
with common laboratory protein contaminants was also added and .raw data files obtained in the
LC-MS/MS analyses were used to search with a SequestHT search engine using Thermo Proteome
Discover (v. 1.4.1.14) against the aforementioned database. Both target and a decoy database
were searched to obtain a false discovery rate (FDR), and thus estimate the number of incorrect
peptide-spectrum matches that exceeded a given threshold, applying preestablished search parameters
(enzyme: trypsin; missed cleavage: 5; fixed modifications: carbamidomethyl of cysteine; variable
modifications: oxidation of methionine; peptide tolerance: 10 ppm and 0.6 Da for MS and MS/MS
spectra, respectively). To improve the sensitivity of the database search, the semi-supervised learning
machine Percolator was used in order to discriminate correct from incorrect peptide spectrum matches.
Percolator assigns a q-value to each spectrum, which is defined as the minimal FDR at which the
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identification is deemed correct (0.01, strict; 0.05, relaxed). These q values are estimated using the
distribution of scores from decoy database search.
2.8. Transmission Electron Microscopy (TEM) of Cell Sections
pRBC cultures were treated with 0.5 mg PAA/mL at 37 ◦C for 90 min, when cryosections were
prepared as described [11]. Collected cryosections were incubated at RT on drops of 2% gelatin in 0.1 M
PHEM buffer [27] for 30 min at 37 ◦C, followed by (all solutions in 0.1 M PHEM buffer) 20 mM glycine
for 15 min, 10% fetal bovine serum (FBS) for 10 min, and 1% FBS for 5 min. Then they were incubated
for 1 h in the presence of rabbit ISA23 antiserum diluted 1:500 in 0.1 M PHEM buffer supplemented
with 1% FBS. After three washes on drops of 0.2% FBS in 0.1 M PHEM buffer for 10 min, sections
were incubated for 20 min with anti-rabbit IgG coupled to 12-nm colloidal gold particles (Jackson
ImmunoResearch, West Grove, PA, USA) using a 1:30 dilution in 0.1 M PHEM buffer supplemented
with 1% FBS. This was followed by three washes with drops of 0.1 M PHEM buffer for 10 min, a 5-min
fixation in 1% glutaraldehyde, 0.1 M PHEM buffer, and 10 1-min washes with ddH2O. The observations
were done in a Tecnai Spirit electron microscope (FEI Company, Hillsboro, OR, USA) with a CCD SIS
Megaview III camera. Controls included omission of polymer, omission of anti-PAA antibody, and
staining of non-infected RBCs.
2.9. Determination of PAA-FITC Presence in Blood and Toxicity Assays in Mice
Inbred BALB/cAnNHsd female, 6–8-week-old mice (BALB/c; Harlan Laboratories, Indianapolis,
IN, USA) were dosed orally with 100 mg/kg PAA-FITC dissolved in PBS. Then 15-µL blood samples
were collected in Microvette® tubes (Sarstedt) using the cross-sectional cut method, before dosing
(t0) and at 1, 6, and 24 h post-administration. Blood samples were centrifuged for 5 min (4000 g) and
stored at −20 ◦C; 10 µL of the supernatant were diluted 10 times with PBS and used to measure FITC
fluorescence in a Spectramax Gemini XS microplate fluorimeter (Molecular Devices, LLC, Sunnyvale,
CA, USA; λex/em: 485/530 nm). For in vivo toxicity assays, polymer solutions were prepared in
PBS and each sample was injected intraperitoneally in three BALB/c mice; PBS was administered to
control animals. Mice were individually monitored for eight days following a drug dosage regime
as in the in vivo antimalarial assays performed in this work (see below). In the presence of toxic
effects including, among others, >20% reduction in animal weight, aggressive and unexpected animal
behavior or the presence of blood in feces, animals were immediately anesthetized using a 100 mg/kg
Ketolar plus 5 mg/kg Midazolan mixture and sacrificed by cervical dislocation. Polymer maximum
tolerated dose (MTD) was therefore defined upon completion of the assay as the highest dosage
exhibiting an absence of the aforesaid toxicity signs. All experiments involving mice were performed
in accordance with the corresponding relevant guidelines and regulations. The studies reported
here were performed under protocols reviewed and approved by the Ethical Committee on Clinical
Research from the Hospital Clínic de Barcelona (Reg. HCB/2014/0910; date of approval 14 October
2014). The animal care and use protocols followed adhered to the specific national and international
guidelines specified in the Spanish Royal Decree 53/2013, which is based on the European regulation
2010/63/UE.
2.10. Antimalarial Activity Assay In Vivo
The in vivo antimalarial activity of free CQ and of PAA-CQ conjugates was analyzed in a
four-day blood suppressive test as previously described [28]. Briefly, BALB/c mice were inoculated
intraperitoneally with 2 × 106 RBCs from P. yoelii yoelii 17XL (PyL) MRA-267-infected mice.
Treatment started 2 to 4 h later (day 0) with a single dose of 5 mg CQ kg−1 day−1 administered
as diphosphate-drug or PAA-drug by oral administration followed by identical dose administration
for the next three days. Tested compounds were prepared in PBS and the control groups received PBS.
Parasitemia was monitored daily by microscopic examination of Giemsa-stained thin blood smears.
When all surviving animals had completely cleared Plasmodium infection they were re-infected (on
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day 35) with P. yoelii as above and left untreated. A group of animals infected and left untreated was
always used as a control of a correct parasite inoculation. Survival was monitored until day 62.
2.11. PAA Administration to Mosquitoes
Wild Anopheles atroparvus mosquitoes (ca. 1000 individuals) were collected from a pig farm
in the Ebre delta, in collaboration with the Consorci de Serveis Agroambientals de les comarques del
Baix Ebre i Montsià. Females were arm-fed to produce the next generation of mosquitoes. Newly
hatched female mosquitoes (F1 generation) were starved for 48 h prior to feeding them (day 0) with
ISA1-FITC nanoparticles (0.125 mg/mL) incorporated in their sugar meal (0.1 mg glucose/mL), in a
cage protected from light. Sugar-fed females were separated from non-fed mosquitoes and used in the
experiment (continuously kept in the dark, and with access to sugar water without the labeled polymer).
At different times, females were anesthetized with ether and immobilized live on a microscope slide
with Vaseline and Parafilm® for confocal fluorescence microscopy examination (λex/em: 495/519 nm).
Six to eight female Anopheles gambiae mosquitoes were tested for each PAA-FITC. The mosquitoes
were removed to cups and allowed to feed for two days on 10% sucrose provided in a filter mounted on
a 1-mL syringe. On day 3 the sucrose was replaced with PAA-FITC at a concentration of 0.25 mg/mL
diluted in 10% sucrose. A control was included where the mosquitoes continued to feed on sucrose.
After another three or five days, mosquitoes were dissected and midguts and salivary glands were fixed
in 4% formaldehyde. The dissected organs were viewed under a Zeiss Axioskop 2 Plus microscope
fitted with an Axiovert CCD camera (Zeiss, Oberkochen, Germany).
2.12. Statistical Analysis
Data are presented as the mean ± standard error of at least three independent experiments,
and the corresponding standard errors in histograms are represented by error bars. Percentages of
viability were obtained using non-treated cells as control of survival and IC50 values were calculated
by nonlinear regression with an inhibitory dose-response model using GraphPad Prism5 software.
Concentrations were transformed using natural log for linear regression. Regression models were
adjusted for replicates and assay data.
3. Results
3.1. Characterization of PAAs and Stability Analysis in GIT Conditions
Following synthesis, PAAs were size fractionated to have a range of molecular masses from
5 to 100 kDa, well above the maximum size previously evaluated for intraperitoneal administration
(<25 kDa, [11]). AFM images taken in water on mica surfaces revealed homogeneous dispersions of
particles up to 5 nm in height (Figure 1A). To evaluate their possible degradation during GIT transit,
the polymers were incubated for different times in simulated fasted-state gastric fluid and subjected to
MALDI TOF/TOF analysis, which permitted identification of molecules up to a molecular mass of ca.
7 kDa. Although large polymers escaped detection, this strategy allowed us to follow the degradation
process over time. MALDI chromatograms exhibited regularly spaced peaks (Figure 1C), whose
masses differed by discrete units that corresponded to multiples of the mass of the main building block
of the respective polymers (e.g., 329 Da for ARGO7; Figure 1B). Hydrolytic degradation was evident
after 6 h of incubation (Figure 1D) and reached its maximum at around 19 h (Figure 1E).
The four PAAs, initially synthesized as relatively homogeneously sized preparations, acquired
when dissolved in PBS a higher size and polydispersity according to nanoparticle tracking analysis
(Figure S1), with estimated hydrodynamic diameters between 50 and 400 nm. In the high ionic strength
of PBS, the repulsive forces between the polymer charged groups are screened, thus promoting
macromolecular associations. Scanning electron microscopy analysis of the polymers dissolved in
isopropanol (an aggregation-promoting solvent) revealed branched structures reaching lengths of
several microns (Figure 2). PAAs have relatively large hydrodynamic volumes if compared with
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vinyl polymers of similar mass, indicating a tendency to assume an extended chain conformation
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3.2. Cell Targeting of PAAs
As already reported for smaller polymers [11], in flow cytometry analyses PAAs did not exhibit a
clear affinity for pRBCs vs. the uninfected RBCs present in the same culture (Figure S2). In complete
medium little binding as observed to either cell, but in incomplete medium, PAA-cell interactions
increased with both RBCs and, especially, with late-stage pRBCs (characterized by a stronger Hoechst
signal due to the presence of several parasite daughter cells and therefore a larger DNA content). The
differences in cell targeting observed by flow cytometry between complete and incomplete RPMI
could be related to a screening effect of the proteins present in complete medium, which might prevent
polymer interactions with cell membranes. Indeed, a high level of protein binding has been reported
with the seru substitute Albumax used in complete RPMI [30]. This observation must be taken into
account when designing in vivo experiments due to the high protein concentration found in plasma.
onfocal fluorescence icroscopy exa ination of [P -FIT ]-treated late-stage P. falciparu
cultures indicated that the poly ers accu ulated inside the parasitophorous vacuole here the
arasite is containe (Fig re S3). he absence of fl orescence in the cytosol of arasitize cells
as consistent ith the lack of FI signal in s, altho gh accor ing to flo cyto etry ata in
inco lete I, non- arasitize s significantly interacte ith so e s, es ecially ith
1 and IS 23 (Figure S2). Polyclonal antibodies generated against ISA23 (Figure S4) were used to
investigate potential entry routes of PAAs into pRBCs. Although the antibody signal was not abundant,
it could be occasionally observed associated with the plasma membrane and in intracellular areas not
enclosed by a membrane (Figure S5). These observations reinforced the hypothesis that PAAs traverse
the pRBC lipid bilayer through a diffusion mechanism, as previously suggested from preliminary data
obtained based on the indirect detection of PAA-FITC using a ti-fluorescein a tibodies [11].
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When PAAs were incubated in the presence of macrophages in incomplete RPMI, only ISA23 was
significantly taken up by the cells according to fluorescence microscopy analysis (Figure 3A). This
result is consistent with the observation that ISA23 showed in the same buffer the highest interaction
of all four PAAs with non-infected RBCs. Taken together, these experimental evidences indicate that
ISA23 has a strong affinity for lipid bilayers, as it can be observed in confocal fluorescence microscopy
images of [ISA23-FITC]-treated macrophage cultures where, in addition to cell membranes, also
vesicular extracellular structures were shown to interact with the polymer (Figure 3B). Previous data
showed that ISA23 had a remarkably high blood residence time [15], with about 25% of the polymer
still present in the circulation 24 h after its intraperitoneal administration to mice [11]. This suggested
that despite the incorporation of ISA23 into macrophages, the overall polymer concentration in blood
will not be significantly affected by this cell intake.
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Figure 3. Fluorescence micr scopy analysis of P -FITC uptake by macrophages. (A) Conventional
fluorescence microscopy of all PAA samples. (B) Confocal fluorescence microscopy of the ISA23-FITC
sample. Two macrophages are shown, one with intense intracellular FITC labeling (star) and another
with plasma membrane labeling (arrow). Arrowheads point at some of the abundant vesicular
structures present in the culture that have also incorporated the polymer.
3.3. Affinity Chromatography Analysis of PAA-Binding pRBC Proteins
To investigate the molecular mechanism responsible for the preferential entry of PAAs into pRBCs
vs. RBCs, an affinity chromatography approach was chosen. The four PAAs were functionalized with
sulfhydryl groups that would be used to crosslink the polymers to SulfoLink columns (see Figure 2 for
a SEM control of polymer structures after the incorporation of sulfhydryl groups). Coupling efficacy
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of PAAs to columns was found to range from 50% to 90%. According to silver-stained SDS-PAGE
gels, no proteins could be detected to bind PAA-columns upon loading of uninfected RBC saponin
extracts (Figure 4A). However, after loading the same columns with equal total amounts of identically
prepared pRBC saponin extracts, several bands corresponding to proteins eluted from the affinity
columns could be observed in the silver-stained gels of all four PAAs (Figure 4B). From a Coomassie
Blue gel run in parallel with higher sample amounts loaded, the lanes from the separating gel were
excised and analyzed by LC-MS/MS, where a total of 507 proteins were identified, 365 human and
142 from the P. falciparum 3D7 strain used. Many Plasmodium proteins were found to bind more than
one PAA (see Table S1 for a list of Plasmodium proteins binding two, three, or all four PAAs), and over
one-quarter (37 out of 142) interacted with the four polymers, which strongly validated the specificity
of the identified PAA-protein interactions. Although the identified sequences belonged to a wide
variety of families, it was remarkable the detection of several proteins involved in cell adhesion or
present in the cell membrane, such as glycophorin-binding protein, erythrocyte membrane protein 3,
mature parasite-infected erythrocyte surface antigen, ring-exported protein 1, surface protein P113, and
high molecular weight rhoptry protein 3. We also noted the presence of several heat-shock proteins.
This result strongly suggested the presence in pRBC saponin extracts of adhesive proteins interacting
both with PAAs (hence the binding to affinity columns) and with RBC components (hence the presence
of human RBC proteins in the fractions eluting from the columns loaded with pRBC extracts). This
scenario might also explain the increased uninfected RBC targeting of some PAAs in the presence of
pRBCs (Figure S2), if pRBC-secreted proteins associate with uninfected erythrocytes in the culture, e.g.,
through the extracellular vesicle trafficking that has been described between pRBCs [31].
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In agreement with this hypothesis, we observed in immunoTEM preparations of Plasmodium
intraerythrocytic stages numerous events of what appeared to be the budding from pRBC membranes
of small vesicles below 50 nm in diameter (Figure 5). These structures, also abundantly detected in the
extracellular space, seemed to be formed from protrusions of the outer bilayer leaflet of the plasma
membrane, although from the static TEM images it could not be discerned whether they were leaving
or entering the erythrocyte. Larger lipid bilayer-enclosed vesicles just under 500 nm in diameter that
were detected in the close vicinity of the pRBC plasma membrane (both inside and outside the cell)
were also observed to contain and/or be associated with the smaller vesicles. This vesicular traffic was
less abundant in uninfected RBC control samples, although a detailed quantitative analysis would be
required to confirm this qualitative observation.
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incorporation of drug (Figure S7). SEM images after isopropanol treatment indicated that CQ 
loading resulted in more compact aggregated polymer structures (Figure S8), especially for those 
PAAs carrying more drug, which might be due to a template effect induced on the polymer by the 
cargo. As already described for smaller PAA structures [11], encapsulation did not improve the in 
vitro activity of CQ (Figure S9). Previous data reporting a modest in vitro antimalarial activity of 
some PAAs (particularly AGMA1) [11] led us to explore the suspected antiparasitic mechanism in 
more detail. Based on the known antimalarial activity of certain polymers like heparin, operating 
through inhibition of the RBC invasion by the parasite [32–36], we performed an invasion inhibition 
assay (Figure 6). Whereas the maturation rate of intraerythrocytic P. falciparum in the presence of 
polymers was not significantly affected up to 1 mg PAA/mL, the invasion rate in the presence of 
AGMA1 was clearly reduced in a dose-dependent manner, indicating that most likely the 
antimalarial activity mechanism of this polymer is based, as for heparin, on invasion inhibition. 
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area; c, RBC cytosol; p, Plasmodium. White arrowheads indicate structures in the process of budding
from or merging with RBCs; black arrowheads point at vesicles not fused to RBC membranes. Size
bars represent 500 nm.
None of the polymers was hemolytic or cytotoxic up to 1 mg/mL (Figure S6). MTD assays in
mice confirmed the significant toxicity alread observed for smaller ISA1 polymers at 50 mg/kg [11],
whereas the other structures were well tolerated up to 200 mg/kg. This result was in agreement
with previous data reporting higher toxicity for positively charged PAA dendrimers vs. their anionic
counterparts after oral administratio to mice [9], which led us to discard ISA1 for the preparation of
in vivo tests in mice.
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3.4. In Vitro Plasmodium Growth Inhibition Assays
CQ loaded into AGMA1, ISA23 and ARGO7 polymers reached drug payloads of 14.2%, 32.6%
and 35.6% respectively; these drug contents were confirmed just before performing in vitro and in vivo
assays (15.9%, 32.1% and 36.0% respectively). AFM images taken in water did not reveal significant
changes in the globular structure of the polymeric nanoparticles induced by the incorporation of
drug (Figure S7). SEM images after isopropanol treatment indicated that CQ loading resulted in
more compact aggregated polymer structures (Figure S8), especially for those PAAs carrying more
drug, which might be due to a template effect induced on the polymer by the cargo. As already
described for smaller PAA structures [11], encapsulation did not improve the in vitro activity of CQ
(Figure S9). Previous data reporting a modest in vitro antimalarial activity of some PAAs (particularly
AGMA1) [11] led us to explore the suspected antiparasitic mechanism in more detail. Based on the
known antimalarial activity of certain polymers like heparin, operating through inhibition of the RBC
invasion by the parasite [32–36], we performed an invasion inhibition assay (Figure 6). Whereas the
maturation rate of intraerythrocytic P. falciparum in the presence of polymers was not significantly
affected up to 1 mg PAA/mL, the invasion rate in the presence of AGMA1 was clearly reduced in
a dose-dependent manner, indicating that most likely the antimalarial activity mechanism of this
polymer is based, as for heparin, on invasion inhibition.Pharmaceutic  2018, 10, x FOR PEER REVIEW  14 of 20 
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3.5. Oral Administration to ice
Upon oral administration to mice of PAA-FITC, fluorescence could be detected in the circulation
24 h later (Figure S10A), although we could not rule out artifacts due to potential cleavage of
the PAA-FITC bond during GIT transit. However, the presence in plasma of orally administered
ISA23 could be determined in dot blot assays using ISA23 antiserum (Figure S10B), indicating that at
least this polymer is able to enter the blood circulation when fed to mice.
hen ad inistered orally at 5 g CQ kg−1 day−1, PAA encapsulation only slightly i proved the
activity co pared to the free drug (Figure 7A), ith three ice cured out of five (3/5) for ISA23-C ,
t o out of four for ARGO7-CQ, and two out of five for both AGMA1-CQ and free CQ. When these nine
surviving animals were re-infected with P. yoelii and left untreated, all of them recovered completely,
without presenting symptoms of the disease and with parasitemia levels below microscopy detection
thresholds (Figure 7B). Control naïve infected animals left untreated developed malaria, showing high
levels of parasitemia (Figure S11). This result indicated that the animals had developed immunity
against Plasmodium, a result in agreement with previous reports of i mune protection induced in
alaria-infected mice that had been administered curative drug doses [23].
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Figure 7. In vivo antimalarial activity assays. (A) Kaplan–Meier plot for the in vivo assay of the
effect on P. yoelii-infected mice (n = 5 animals/sample except for ARGO7-CQ, where one of the
infections was not successful) of CQ administered orally at 5 mg kg−1 day−1, either as a free drug
or polymer-conjugated. (B) Microscopic images of blood smears prepared on different days (D0 was
the day of the first infection, and reinfection was on day 35), used to determine parasitemias in a
P. yoelii-infected mouse treated with AGMA1-CQ.
. . ral i istratio to osq itoes
it the aim of exploring radically new antimalarial strategies we decided to investigate if PAAs
could be sed in f ture i novative appro ch s gainst malaria i volving the direct administration
to osquitoes of nanocarriers capable of encapsulating antipl smodial drugs. To obtain additional
preliminary data on the potential effect of PAAs on mosquito viability, we decided to us for this
assay ISA1, which had shown the hig est in vivo toxicity in mice. Whe A. atroparvus mosquitoes
were fed ISA1-FITC incorporated in their sugar meal, the polymer fluorescence co ld be detected one
ay after i gestion in the insect gut (Figure 8A) and thre days post-fe ding in b dy tissues outsi e
of th gut, including a location in the thorax, near the ead, i the vicinity of the salivary glands
(Figure 8B). ISA1-FITC seemed to diffuse through the midgut and circulate via the hemolymph and
was detected up to six days after its ingestion, being the thorax regio w re fluorescence lasted
longer. In a similar feeding assay done with A. gambiae, dissection of the mosquito organs revealed the
presence of AGMA1-FITC, ARGO7-FITC and IS 23-FITC in the midgut but not in the salivary glands
(Figures S12 and S13). No significant effect n mosquito lif span was observ d for any of the PAAs.
Preliminary targeting assays of PAA-FITC to mosquito stages of Plasmodium (P. falciparum
gametocytes and Plasmodium berghei ookinetes, oocysts and sporozoites) did not reveal PAAs binding
directly to any of these parasite forms (Figures S14–S17).
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4. Discussion
The four PAAs assayed her interact with protei s belonging to the chaperone and
glycophorin-binding famili . Ch perones are required in a multitude of biological systems for
the correct folding of proteins; in particular Hsp70 and Hsp90 facilitate the assembly of proteins into
higher order complexes and their translocation across membranes [37]. The key role of chaperones in
the cell suggests that part of the modest antimalarial activity of some PAAs might be based on their
binding to intracellular components. Such a scenario is consistent with the finding that AGMA1, whose
antimalarial activity is highest [11], is also the PAA associating with a larger number of Plasmodium
proteins (Table S1). The binding of PAAs to parasite ligands is unlikely to be based on unspecific
electrostatic interactions, because ISA1 and AGMA1, whose cationic character is similar (both have
an average of 0.55 positive charges per unit at pH 7.4), share only about 55% of the identified affinity
chromatography purified proteins. A significant portion of AGMA1 did show hepatic localization
after intravenous injection in mice [15], which presents this polymer as an interesting candidate for
therapies targeting the dormant liver stages (hypnozoites) of some Plasmodium species.
The first glycophorin-binding protein identified in Plasmodium was GBP130 [38], which has been
shown to play a role in decreasing the membrane rigidity of pRBCs, a process involved in protein
trafficking. Being glycophorin a receptor for the malaria parasite during its adhesion to red blood
cells [39], the finding that PAAs associate with the parasite-encoded glycophorin-binding protein can
open new therapeutic avenues based on blocking Plasmodium–red blood cell interactions. Invasion
inhibition assays showed that AGMA1, at non-toxic concentrations that do not affect the maturation
of intraerythrocytic P. falciparum, does reduce invasion rates in a dose-dependent manner. Among
other proteins identified to bind several PAAs are the surface protein P113 and the high molecular
weight rhoptry protein 2. The coupling of PAAs to these ligands might mask essential interactions of
Plasmodium with the RBC membrane, blocking or significantly slowing down invasion. The resulting
increased exposure of the parasite to the immune system might partially contribute to the protection
against malaria infection observed in [PAA-CQ]-treated mice. This knowledge could be applied to the
design of new antimalarial approaches where PAAs might play a dual role as carriers of drugs and as
vaccination adjuvants. Regarding potential future clinical applications, it is relevant that this effect
is obtained following oral intake, since this is the preferred form of administration of treatments for
non-complicated malaria.
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Contrary to intact erythrocytes, which lack endocytosis of large macromolecules, pRBCs develop
mechanisms that confer an increased permeability to particles up to 70 nm across [40,41], which might
permit the entry of PAAs below that size. This limitation leaves a narrow margin for the design of
orally administered antimalarial nanocarriers, which must be synthesized with a sufficiently large
size to reach the GIT without significant degradation whereas once in the blood circulation they
need not be larger than a few dozen nm. PAAs, however, could be more readily adaptable to the
treatment of other blood-infecting pathogens whose host cell is not the erythrocyte. The prevailingly
anionic polymer ISA23 exhibited the clearest interaction with cell membranes from both RBCs and
macrophages, being massively endocytosed by the latter. Such capacity presents this polymer as an
interesting candidate for the coencapsulation, oral administration, and targeted delivery of drugs to
treat common coinfections of pathogens parasitizing these two cell types, such as Plasmodium and the
macrophage-infecting Leishmania.
The modest amelioration in the antimalarial activity of orally administered CQ provided by
encapsulation in PAA polymers could be significantly improved in different ways. An increased
specificity of delivery can be obtained upon functionalization of the nanocarriers with targeting molecules,
e.g., antibodies against either pRBCs [20] or both parasitized and non-parasitized erythrocytes [25], or
glycosaminoglycans such as heparin, which has shown specific pRBC binding [42,43]. On the other
hand, coating of the nanovessels with polyethylene glycol (PEG) is a standard method used to reduce
immune clearance and thereby increase circulation times allowing the carriers to reach their target
site [44]. Nevertheless, this last strategy has to be more thoroughly explored because PEGylation of
anionic PAA dendrimers has been described to lead to a significant decrease in intestinal cell uptake [7].
The proof-of-concept approach researched here using CQ can be extrapolated to other drugs being less
efficient, more toxic, or still undiscovered. The finding that PAA encapsulation did slightly improve the
exceptionally good performance of CQ as antimalarial opens perspectives for the successful application
of these polymers to future orally administered therapeutic and/or prophylactic strategies.
A largely unexplored avenue in antimalarial drug development is targeting the parasite stages
in the insect vector itself [45]. Preliminary data following feeding of PAA-FITC to A. atroparvus
and A. gambiae indicate that the ingested polymers are not immediately excreted and have a long
residence time in the midgut of both species, and in the case of A. atroparvus other locations in the
vicinity of the salivary glands seem likely. Mosquito-dwelling parasite stages could be efficiently
reached by specifically targeted nanovectors (e.g., tagged with heparin, which has been shown to
bind Plasmodium ookinetes [43]) encapsulating the corresponding drugs. Although more studies
are required, including a characterization of the longevity of nanocarriers inside the mosquito, our
results suggest that encapsulated antimalarial drugs could be directly dispensed to Anopheles from
fixed-volume containers where the drug does not become diluted with time as when it is in the blood
circulation. This strategy not contemplating administration to humans would significantly reduce
clinical trials and treatment development costs, thus allowing for faster transferability.
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